Cannabis producer Cresco Labs has resolved a weeks-long labor dispute in Pennsylvania, securing peace with its workforce at a significant price. While the new union agreement brings stability, recently released annual figures expose substantial challenges within the company’s financial statements, driven by substantial impairments and a tough operating climate.
Financial Performance Overshadowed by Impairments
The company’s fiscal year 2025 results, released alongside news of the labor settlement, revealed a net loss of $140 million on total revenue of $656 million. A critical factor in the fourth quarter alone was a non-cash impairment charge of $93 million related to its operations in New York State. This drove a net loss of $89 million for that period, despite the generation of $27 million in operating cash flow.
Key financial metrics for the year include:
– Total Revenue: $656 million
– Net Loss: $140 million
– Adjusted EBITDA Margin (Q4): 25%
– Cash on Hand: $91 million
– Long-Term Debt: approximately $311 million
Labor Strike Concludes with Substantial Concessions
The period of uncertainty at a key retail location ended after Cresco reached a new collective bargaining agreement with Teamsters Local 429. The deal covers employees at the Sunnyside dispensary in Wyomissing, Pennsylvania, following a strike that commenced in late February. Workers secured a wage increase of 12.5%, alongside enhanced healthcare benefits and additional paid vacation time.
Should investors sell immediately? Or is it worth buying Cresco Labs?
This resolution underscores the mounting cost pressures across the U.S. cannabis industry, where labor is increasingly successful in negotiating for improved compensation and working conditions.
Strategic Shifts and Regulatory Catalysts
Cresco Labs is navigating a complex market environment. The company has exited the California market and regulatory adjustments in Michigan have impacted revenue. Management anticipates a high single-digit percentage sequential decline in revenue for the first quarter of 2026.
A potential major catalyst for the entire sector remains the possible reclassification of cannabis at the federal level from Schedule I to Schedule III. Such a move would dramatically reduce the industry’s tax burden. Concurrently, Cresco is pursuing geographic diversification to lessen its reliance on the U.S. market; it launched its flagship brand into Germany’s medical cannabis sector in late 2025.
The company is scheduled to report its Q1 2026 results on May 20, 2026. Current analyst estimates project a loss per share in the range of $0.02 to $0.04.
Ad
Cresco Labs Stock: Buy or Sell?! New Cresco Labs Analysis from April 2 delivers the answer:
The latest Cresco Labs figures speak for themselves: Urgent action needed for Cresco Labs investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 2.
Cresco Labs: Buy or sell? Read more here...
